Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (NASDAQ: DTIL) has announced encouraging results from its Phase 1/2a study of PBCAR0191, targeting relapsed/refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Enhanced lymphodepletion strategy improved the overall response rate (83%) and complete response rate (CR) among heavily pretreated subjects. Data will be presented at the ASH Annual Meeting on December 11-14, 2021. Notably, 80% of B-ALL patients responded positively, indicating potential for bridging to stem cell transplant.
Precision BioSciences, Inc. (DTIL) announced it will publish its financial results for Q3 2021 on November 10, 2021, and provide a business update. CEO Michael Amoroso will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. The company utilizes its ARCUS® genome editing platform for developing CAR T and in vivo gene editing therapies targeting genetic and infectious diseases. Investors can access a live webcast of the chat on the company’s website.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit on October 27, 2021, from 1:30 to 1:55 ET. The company reported a cash balance of approximately $160.5 million as of September 30, 2021, expected to support operations into 2023. The presentation will be available via webcast on the company’s investor website, with an archived replay for about 30 days.
Precision BioSciences, a clinical-stage biotech company (NASDAQ: DTIL), announced an inducement grant for Michael Amoroso, its new President and CEO. The grant includes options to purchase 850,000 shares and restricted stock units valued at $237,000. The stock option has a 10-year term, with 25% vesting on October 15, 2022, and the remainder vesting quarterly over three years. Both awards comply with the company's 2021 Employment Inducement Incentive Award Plan, approved by the Compensation Committee.
Precision BioSciences (NASDAQ: DTIL) announced Michael Amoroso as the new President and CEO, effective October 15, 2021, succeeding Co-Founder Matt Kane. Amoroso brings extensive experience in operational management and commercial roles within gene and cell therapies, particularly in oncology. His leadership is expected to enhance the company's ARCUS genome editing platform and advance late-stage clinical strategies. The Board of Directors commended Kane's significant contributions to the company.
Precision BioSciences (DTIL), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The pre-recorded presentation will be available for on-demand viewing on September 13, 2021, at 7:00 a.m. ET on the company’s website. Precision BioSciences focuses on developing allogeneic CAR T and in vivo gene correction therapies using its proprietary ARCUS® genome editing platform, targeting genetic and infectious diseases with its innovative pipeline.
Precision BioSciences (DTIL) has accelerated its clinical development, expecting three new drug applications within three years targeting familial hypercholesterolemia, primary hyperoxaluria type 1, and chronic hepatitis B. A licensing agreement with iECURE aims to advance PBGENE-PCSK9 through Phase 1 trials, while preclinical data showcases their ARCUS genome editing platform's precision. The company has approximately $167 million in cash, sufficient to fund operations into 2023.
Precision BioSciences has partnered with iECURE to license its PCSK9-directed ARCUS nuclease, aiming to advance the PBGENE-PCSK9 candidate for treating familial hypercholesterolemia into Phase 1 clinical trials as early as 2022. Precision retains rights to all indications related to PBGENE-PCSK9 while iECURE gains access to develop therapies for four rare genetic liver diseases. Additionally, Precision will secure equity in iECURE and potential milestone and royalty payments from product sales.
Precision BioSciences (Nasdaq: DTIL) has secured an exclusive license from Tiziana Life Sciences (Nasdaq: TLSA) to utilize foralumab, a human anti-CD3 monoclonal antibody, as a lymphodepletion agent in its allogeneic CAR T therapy development. The collaboration aims to enhance the therapeutic effectiveness of CAR T cells by improving their tolerance and long-term persistence. Precision will oversee the development and commercialization of foralumab, providing Tiziana with upfront, milestone, and royalty payments.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced its inaugural R&D event on September 9, 2021, at 8:00 am ET, focusing on in vivo gene editing. The event will feature management presentations and guest speakers, highlighting the company's development strategy and progress in in vivo gene editing projects. Attendees can expect insights on the ARCUS gene editing platform, pre-clinical data, and collaboration updates. Registration for the live webcast is available on the company’s investor website, with a replay accessible for one year post-event.